Therapeutic Targeting of Pattern Recognition Receptors to Modulate Inflammation in Atherosclerosis

被引:0
|
作者
Su, Hongyan [1 ]
Wang, Xiancheng [1 ]
Wang, Lu [1 ]
Yuan, Na [2 ]
机构
[1] Changchun Univ Chinese Med, Cardiol Dept, Affiliated Hosp 3, Changchun 130000, Peoples R China
[2] Changchun Univ Chinese Med, Rheumatol Dept, Affiliated Hosp, Changchun 30000, Peoples R China
关键词
Atherosclerosis; Cardiovascular diseases; Pattern recognition receptor; Toll-like receptor; LOW-DENSITY-LIPOPROTEIN; NLRP3; INFLAMMASOME; ENDOTHELIAL-CELLS; ATTENUATES ATHEROSCLEROSIS; CIRCULATING MONOCYTES; AIM2; EXPRESSION; CHOLESTEROL; MICE; ACTIVATION;
D O I
10.1007/s12013-024-01481-9
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Atherosclerosis (AS), a potentially fatal cardiovascular disease (CVD), is a chronic inflammatory condition. The disease's onset and progression are influenced by inflammatory and immunological mechanisms. The innate immune pathways are essential in the progression of AS, as they are responsible for detecting first danger signals and causing long-term changes in immune cells. The innate immune system possesses distinct receptors known as pattern recognition receptors (PRRs) which can identify both pathogen-associated molecular patterns and danger-associated molecular signals. Activation of PRRs initiates the inflammatory response in various physiological systems, such as the cardiovascular system. This review specifically examines the contribution of the innate immune response and PRRs to the formation and advancement of AS. Studying the role of these particular receptors in AS would enhance our understanding of the development of AS and offer novel approaches for directly improving the inflammatory response associated with it.
引用
收藏
页码:73 / 86
页数:14
相关论文
共 50 条
  • [21] Pattern recognition receptors in chronic pain: Mechanisms and therapeutic implications
    Kato, Jungo
    Agalave, Nilesh M.
    Svensson, Camilla I.
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2016, 788 : 261 - 273
  • [22] Unveiling the therapeutic potential of miR-146a: Targeting innate inflammation in atherosclerosis
    Ardinal, Azizah Puspitasari
    Wiyono, Alice Valeria
    Estiko, Reza Ishak
    JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2024, 28 (19)
  • [23] Potential Therapeutic Targeting of Platelet-Mediated Cellular Interactions in Atherosclerosis and Inflammation
    Nagy, B., Jr.
    Miszti-Blasius, K.
    Kerenyi, A.
    Clemetson, K. J.
    Kappelmayer, J.
    CURRENT MEDICINAL CHEMISTRY, 2012, 19 (04) : 518 - 531
  • [24] Lysophospholipid Receptors, as Novel Conditional Danger Receptors and Homeostatic Receptors Modulate Inflammation-Novel Paradigm and Therapeutic Potential
    Wang, Xin
    Li, Ya-Feng
    Nanayakkara, Gayani
    Shao, Ying
    Liang, Bin
    Cole, Lauren
    Yang, William Y.
    Li, Xinyuan
    Cueto, Ramon
    Yu, Jun
    Wang, Hong
    Yang, Xiao-Feng
    JOURNAL OF CARDIOVASCULAR TRANSLATIONAL RESEARCH, 2016, 9 (04) : 343 - 359
  • [25] THERAPEUTIC TARGETING OF INFLAMMATION
    Platzbecker, U.
    LEUKEMIA RESEARCH, 2023, 128
  • [26] The role of pattern recognition receptors in amyloid-beta-induced inflammation
    Loizou, F.
    Triantafilou, K.
    Morgan, P. B.
    Martha, T.
    IMMUNOLOGY, 2013, 140 : 129 - 129
  • [27] Inflammation as a Therapeutic Target in Atherosclerosis
    Nguyen, Mau T.
    Fernando, Sanuja
    Schwarz, Nisha
    Tan, Joanne T. M.
    Bursill, Christina A.
    Psaltis, Peter J.
    JOURNAL OF CLINICAL MEDICINE, 2019, 8 (08)
  • [28] Targeting Sirtuin to Modulate Human Inflammation
    Suffredini, Anthony F.
    CRITICAL CARE MEDICINE, 2015, 43 (06) : 1348 - 1349
  • [29] Imaging inflammation in atherosclerosis by targeting MCP-1-receptors to identify vulnerable plaques
    Hartung, D
    Petrov, A
    Kolodgie, F
    Narula, N
    Haider, N
    Virmani, R
    Strauss, W
    Narula, J
    CIRCULATION, 2003, 108 (17) : 224 - 224
  • [30] Pattern recognition receptors as therapeutic targets for bacterial, viral and fungal sepsis
    Yuki, Koichi
    Koutsogiannaki, Sophia
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2021, 98